Parekh, P
Int J Mol Sci 24(1):158 Chen L, Xu H, Zhang C, He J, Wang Y (2024) Semaglutide alleviates early brain injury following subarachnoid hemorrhage by suppressing ferroptosis and neuroinflammation via SIRT1 pathway
Throughout the 0-32 week treatment period, adverse outcomes and the occurrence of anti-cagrillintide antibodies were assessed in addition to any changes in systolic and diastolic blood pressure, pulse rate, plasma high-sensitivity C-reactive protein, aldosterone, and the activity of renin
By month 2, the majority of users report mild or zero nausea despite continuing treatment
This includes being aware of the risks of semaglutide and other mental health concerns
In an extension study named FINE-ONE clinical trial, a phase 3 trial involving adults who had type 1 diabetes, CKD & albuminuria and were receiving an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB), Finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo